Gyre Therapeutics (GYRE) Net Cash Flow Growth (3y) (2013 - 2026)
Powered by 
Analysis
Gyre Therapeutics (GYRE) Net Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -8.34% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 36.60% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -35.85% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 106.37% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 67.39% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 4.55% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 52.78% |
| 10 | Gyre Therapeutics | 691.38 Mn | 633.98 Mn | 26.90 Mn | 0.09% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 0.09% |
| Mar 31, 2026 | 26.69% |
| Dec 31, 2025 | 49.52% |
| Sep 30, 2025 | 30.29% |
| Jun 30, 2025 | -29.65% |
| Mar 31, 2025 | 32.65% |
| Dec 31, 2024 | 36.47% |
| Sep 30, 2024 | 71.44% |
| Jun 30, 2024 | -13.04% |
| Mar 31, 2024 | -27.44% |
| Dec 31, 2023 | 54.21% |
| Sep 30, 2023 | 26.42% |
| Jun 30, 2023 | 14.15% |
| Mar 31, 2023 | -27.87% |
| Dec 31, 2022 | -52.06% |
| Sep 30, 2022 | -124.45% |
| Jun 30, 2022 | 93.87% |
| Mar 31, 2022 | -15.48% |
| Dec 31, 2021 | -45.73% |
| Sep 30, 2021 | -10.71% |